Chengdu Olymvax Biopharmaceuticals (SH:688319) Xin Lang Cai Jing·2025-12-12 06:40Group 1 - The company has submitted an application for H-share listing on the Hong Kong Stock Exchange, with relevant documents published on the exchange's website [1] - The company's core product, the tetanus vaccine, generated revenues of approximately 438 million yuan, 463 million yuan, 536 million yuan, and 268 million yuan for the years 2022, 2023, 2024, and the first half of 2025 respectively, maintaining the top ranking in batch issuance in China during this period [1] - The company has established direct commercial relationships with over 2,000 district and county-level disease control centers across 30 provinces, municipalities, and autonomous regions in China [1] Group 2 - The company's candidate vaccine for golden staphylococcus, rFSAV, is the world's first of its kind and is currently undergoing Phase III clinical trials, with all 6,014 participants enrolled as of May 2025 [1] - The company expects to unblind clinical data in the first half of 2026 and plans to submit a New Drug Application (NDA) to the National Medical Products Administration in the second half of 2026 [1] - If approved, rFSAV is anticipated to be the first vaccine globally for the prevention of Staphylococcus aureus infections, with significant potential for overseas licensing opportunities due to the company's strong international business development capabilities [1]